{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:10:04Z","timestamp":1788930604414,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40120-026-00894-3","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:25:22Z","timestamp":1770391522000},"page":"701-716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Impact of Cenobamate on Cognition, Adaptive Behavior, and Quality of Life in Patients with Tuberous Sclerosis Complex"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2444-8761","authenticated-orcid":false,"given":"Francesca Felicia","family":"Operto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia Maria Giovanna","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Charlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Moavero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Mungo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Sammara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"894_CR1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","volume":"19","author":"E Perucca","year":"2020","unstructured":"Perucca E, Brodie MJ, Kwan P, Tomson T. 30\u00a0years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19:544\u201356. https:\/\/doi.org\/10.1016\/S1474-4422(20)30035-1.","journal-title":"Lancet Neurol"},{"key":"894_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2174\/1871527321666220113110044","volume":"22","author":"MA Barbieri","year":"2023","unstructured":"Barbieri MA, Perucca E, Spina E, Rota P, Franco V. Cenobamate: a review of its pharmacological properties, clinical efficacy and tolerability profile in the treatment of epilepsy. CNS Neurol Disord Drug Targets. 2023;22:394\u2013403. https:\/\/doi.org\/10.2174\/1871527321666220113110044.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"894_CR3","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/epi.16718","volume":"61","author":"M Guignet","year":"2020","unstructured":"Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia. 2020;61:2329\u201339. https:\/\/doi.org\/10.1111\/epi.16718.","journal-title":"Epilepsia"},{"key":"894_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38\u201348.","journal-title":"Lancet Neurol"},{"key":"894_CR5","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, et al. Randomized phase\u00a02 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94:e2311\u201322.","journal-title":"Neurology"},{"key":"894_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase\u00a03, multicenter, open-label safety study. Epilepsia. 2020;61:1099\u2013108.","journal-title":"Epilepsia"},{"issue":"3","key":"894_CR7","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/epi4.70021","volume":"10","author":"S Rheims","year":"2025","unstructured":"Rheims S, Steinhoff BJ, Hirsch E, et al. Real-world effectiveness and tolerability of cenobamate in drug-resistant epilepsy: a retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom. Epilepsia Open. 2025;10(3):736\u201348. https:\/\/doi.org\/10.1002\/epi4.70021.","journal-title":"Epilepsia Open"},{"key":"894_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","volume":"112","author":"KL Makridis","year":"2023","unstructured":"Makridis KL, Kaindl AM. Real-world experience with cenobamate: a systematic review and meta-analysis. Seizure. 2023;112:1\u201310. https:\/\/doi.org\/10.1016\/j.seizure.2023.09.006.","journal-title":"Seizure"},{"key":"894_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.950171","volume":"13","author":"KL Makridis","year":"2022","unstructured":"Makridis KL, Bast T, Prager C, et al. Real-world experience treating pediatric epilepsy patients with cenobamate. Front Neurol. 2022;13:950171. https:\/\/doi.org\/10.3389\/fneur.2022.950171.","journal-title":"Front Neurol"},{"issue":"5","key":"894_CR10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1111\/epi.18308","volume":"66","author":"E Buhleier","year":"2025","unstructured":"Buhleier E, Schubert-Bast S, Knake S, et al. A multicenter cohort study on the efficacy, retention, and tolerability of cenobamate in patients with developmental and epileptic encephalopathies. Epilepsia. 2025;66(5):1519\u201328. https:\/\/doi.org\/10.1111\/epi.18308.","journal-title":"Epilepsia"},{"key":"894_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110660","volume":"172","author":"AW Pong","year":"2025","unstructured":"Pong AW, Wehland M, Klein P. Efficacy, safety and tolerability of adjunctive cenobamate in pediatric and adult patients with Lennox Gastaut syndrome. Epilepsy Behav. 2025;172:110660. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110660.","journal-title":"Epilepsy Behav"},{"key":"894_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pediatrneurol.2024.09.023","volume":"161","author":"G Aungaroon","year":"2024","unstructured":"Aungaroon G, Cooke A, Ritter D, Krueger D, Horn P, Franz DN. Cenobamate\u2019s efficacy for seizure treatment in tuberous sclerosis complex. Pediatr Neurol. 2024;161:201\u20137. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.09.023.","journal-title":"Pediatr Neurol"},{"issue":"17","key":"894_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179339","volume":"22","author":"N Specchio","year":"2021","unstructured":"Specchio N, Pietrafusa N, Vigevano F. Is cenobamate the breakthrough we have been wishing for? Int J Mol Sci. 2021;22(17):9339. https:\/\/doi.org\/10.3390\/ijms22179339.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"894_CR14","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1111\/epi.18357","volume":"66","author":"S Lattanzi","year":"2025","unstructured":"Lattanzi S, Dono F, d\u2019Orsi G, et al. Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: interim results after 24-week observational period from the BLESS study. Epilepsia. 2025;66(7):2239\u201352. https:\/\/doi.org\/10.1111\/epi.18357.","journal-title":"Epilepsia"},{"key":"894_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.778410","volume":"12","author":"FF Operto","year":"2021","unstructured":"Operto FF, Pastorino GMG, Pippa F, et al. Psychiatric symptoms and parental stress in children and adolescents with epilepsy. Front Neurol. 2021;12:778410. https:\/\/doi.org\/10.3389\/fneur.2021.778410.","journal-title":"Front Neurol"},{"key":"894_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejpn.2021.04.004","volume":"32","author":"FF Operto","year":"2021","unstructured":"Operto FF, Pastorino GMG, Di Bonaventura C, et al. Effects of antiseizure monotherapy on visuospatial memory in pediatric age. Eur J Paediatr Neurol. 2021;32:106\u201314. https:\/\/doi.org\/10.1016\/j.ejpn.2021.04.004.","journal-title":"Eur J Paediatr Neurol"},{"key":"894_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696946","volume":"12","author":"FF Operto","year":"2021","unstructured":"Operto FF, Vivenzio V, Scuoppo C, et al. Perampanel and visuospatial skills in children with epilepsy. Front Neurol. 2021;12:696946. https:\/\/doi.org\/10.3389\/fneur.2021.696946.","journal-title":"Front Neurol"},{"issue":"2-3","key":"894_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.eplepsyres.2008.10.012","volume":"83","author":"G Coppola","year":"2009","unstructured":"Coppola G, Grosso S, Verrotti A, et al. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. Epilepsy Res. 2009;83(2\u20133):112\u20136. https:\/\/doi.org\/10.1016\/j.eplepsyres.2008.10.012.","journal-title":"Epilepsy Res"},{"issue":"2","key":"894_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","volume":"38","author":"PJ Serrano-Castro","year":"2024","unstructured":"Serrano-Castro PJ, Ram\u00edrez-Garc\u00eda T, Cabezudo-Garcia P, Garcia-Martin G, De La Parra J. Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study. CNS Drugs. 2024;38(2):141\u201351. https:\/\/doi.org\/10.1007\/s40263-024-01063-6.","journal-title":"CNS Drugs"},{"key":"894_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109605","volume":"151","author":"GL Krauss","year":"2024","unstructured":"Krauss GL, Chung SS, Ferrari L, Stern S, Rosenfeld WE. Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase\u00a02 and phase\u00a03 clinical studies. Epilepsy Behav. 2024;151:109605. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109605.","journal-title":"Epilepsy Behav"},{"key":"894_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.seizure.2022.10.004","volume":"102","author":"E Schuetz","year":"2022","unstructured":"Schuetz E, Wagner K, Metternich B, et al. Effects of cenobamate on cognitive performance of epilepsy patients. Seizure. 2022;102:129\u201333. https:\/\/doi.org\/10.1016\/j.seizure.2022.10.004.","journal-title":"Seizure"},{"issue":"1","key":"894_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/epi4.12857","volume":"9","author":"J Catal\u00e1n-Aguilar","year":"2024","unstructured":"Catal\u00e1n-Aguilar J, Hampel KG, Cano-L\u00f3pez I, et al. Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy. Epilepsia Open. 2024;9(1):223\u201335. https:\/\/doi.org\/10.1002\/epi4.12857.","journal-title":"Epilepsia Open"},{"issue":"3","key":"894_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/13554794.2024.2366472","volume":"30","author":"JA Witt","year":"2024","unstructured":"Witt JA, Moskau-Hartmann S, Olaciregui Dague K, Surges R, Helmstaedter C. Severe memory decline along with unaffected executive functions under 400\u00a0mg\/day of cenobamate leading to a collapse in school performance. Neurocase. 2024;30(3):91\u20136. https:\/\/doi.org\/10.1080\/13554794.2024.2366472.","journal-title":"Neurocase"},{"issue":"9","key":"894_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40263-025-01196-2","volume":"39","author":"JA Witt","year":"2025","unstructured":"Witt JA, Badr M, Surges R, von Wrede R, Helmstaedter C. The effects of cenobamate and its dosage on cognition: a retrospective longitudinal study in 84 individuals with epilepsy. CNS Drugs. 2025;39(9):893\u2013902. https:\/\/doi.org\/10.1007\/s40263-025-01196-2.","journal-title":"CNS Drugs"},{"key":"894_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109292","volume":"221","author":"WS Song","year":"2022","unstructured":"Song WS, Cho YS, Oh SP, Yoon SH, Kim YS, Kim MH. Cognitive and behavioral effects of the anti-epileptic drug cenobamate (YKP3089) and underlying synaptic and cellular mechanisms. Neuropharmacology. 2022;221:109292. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109292.","journal-title":"Neuropharmacology"},{"key":"894_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","volume":"96","author":"C Brandt","year":"2022","unstructured":"Brandt C, S\u00e1nchez-\u00c1lvarez JC, Steinhoff BJ, Milanov I, Serratosa JM. Efficacy and safety of adjunctive cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure. 2022;96:86\u201393. https:\/\/doi.org\/10.1016\/j.seizure.2022.02.003.","journal-title":"Seizure"},{"key":"894_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2022.01.001","volume":"129","author":"T Elliott","year":"2022","unstructured":"Elliott T, Ridley-Pryor T, Gienapp AJ, Wheless JW. Initial real-world experience with cenobamate in adolescents and adults: a single center experience. Pediatr Neurol. 2022;129:19\u201323. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2022.01.001.","journal-title":"Pediatr Neurol"},{"key":"894_CR28","volume-title":"WAIS-IV administration and scoring manual","author":"D Wechsler","year":"2008","unstructured":"Wechsler D. WAIS-IV administration and scoring manual. San Antonio: The Psychological Corporation; 2008."},{"key":"894_CR29","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.yebeh.2005.08.015","volume":"7","author":"MT Lutz","year":"2005","unstructured":"Lutz MT, Helmstaedter C. EpiTrack: tacking cognitive side effects of medication on attention and executive functions in patients with epilepsy. Epilepsy Behav. 2005;7:708\u201314.","journal-title":"Epilepsy Behav"},{"key":"894_CR30","doi-asserted-by":"crossref","unstructured":"Sparrow SS, Cicchetti DV, Balla DA. Vineland adaptive behavior scales: second edition (Vineland II), survey interview form\/caregiver rating form. Livonia: Pearson Assessments; 2005.","DOI":"10.1037\/t15164-000"},{"issue":"7","key":"894_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.seizure.2005.07.008","volume":"14","author":"E Beghi","year":"2005","unstructured":"Beghi E, Niero M, Roncolato M. Validity and reliability of the Italian version of the Quality-of-Life in Epilepsy Inventory (QOLIE-31). Seizure. 2005;14(7):452\u20138.","journal-title":"Seizure"},{"key":"894_CR32","unstructured":"Guarino A, Laghi F, Serantoni G, Di Blasio P, Camisasca E. Parenting Stress Index-Fourth Edition (PSI-4). Firenze: Giunti O.S.; 2016."},{"issue":"11-12","key":"894_CR33","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/14737175.2023.2171291","volume":"22","author":"F Villani","year":"2022","unstructured":"Villani F, Cianci V, Di Bonaventura C, et al. Use of cenobamate for the treatment of focal epilepsy: an Italian expert opinion paper. Expert Rev Neurother. 2022;22(11\u201312):935\u201340. https:\/\/doi.org\/10.1080\/14737175.2023.2171291.","journal-title":"Expert Rev Neurother"},{"key":"894_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1668382","volume":"16","author":"FF Operto","year":"2025","unstructured":"Operto FF, Izzo V, Assenza G, et al. Clinical predictors and concomitant antiseizure medications effects on seizure control in relation to plasma cenobamate concentration: a multicenter retrospective study. Front Pharmacol. 2025;16:1668382. https:\/\/doi.org\/10.3389\/fphar.2025.1668382.","journal-title":"Front Pharmacol"},{"key":"894_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109607","volume":"152","author":"MP Zanaboni","year":"2024","unstructured":"Zanaboni MP, Pasca L, Bergamoni S, et al. The effect of executive function on health related quality of life in children with self-limited epilepsy with centrotemporal spikes. Epilepsy Behav. 2024;152:109607. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109607.","journal-title":"Epilepsy Behav"},{"key":"894_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejpn.2020.06.019","volume":"28","author":"FF Operto","year":"2020","unstructured":"Operto FF, Pastorino GMG, Mazza R, et al. Social cognition and executive functions in children and adolescents with focal epilepsy. Eur J Paediatr Neurol. 2020;28:167\u201375. https:\/\/doi.org\/10.1016\/j.ejpn.2020.06.019.","journal-title":"Eur J Paediatr Neurol"},{"key":"894_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106879","volume":"103","author":"FF Operto","year":"2020","unstructured":"Operto FF, Pastorino GMG, Mazza R, et al. Perampanel tolerability in children and adolescents with focal epilepsy: effects on behavior and executive functions. Epilepsy Behav. 2020;103:106879. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106879.","journal-title":"Epilepsy Behav"},{"key":"894_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106648","volume":"102","author":"FF Operto","year":"2020","unstructured":"Operto FF, Schubert-Bast GMG, Mazza R, et al. Effects on executive functions of antiepileptic monotherapy in pediatric age. Epilepsy Behav. 2020;102:106648. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106648.","journal-title":"Epilepsy Behav"},{"key":"894_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1239152","volume":"14","author":"N Pietrafusa","year":"2023","unstructured":"Pietrafusa N, Falcicchio G, Russo E, et al. Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence? Front Pharmacol. 2023;14:1239152. https:\/\/doi.org\/10.3389\/fphar.2023.1239152.","journal-title":"Front Pharmacol"},{"issue":"2","key":"894_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/ane.13106","volume":"140","author":"FF Operto","year":"2019","unstructured":"Operto FF, Mazza R, Pastorino GMG, Campanozzi S, Verrotti A, Coppola G. Parental stress in a sample of children with epilepsy. Acta Neurol Scand. 2019;140(2):87\u201392. https:\/\/doi.org\/10.1111\/ane.13106.","journal-title":"Acta Neurol Scand"},{"key":"894_CR41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.yebeh.2019.03.029","volume":"94","author":"FF Operto","year":"2019","unstructured":"Operto FF, Mazza R, Pastorino GMG, Campanozzi S, Margari L, Coppola G. Parental stress in pediatric epilepsy after therapy withdrawal. Epilepsy Behav. 2019;94:239\u201342. https:\/\/doi.org\/10.1016\/j.yebeh.2019.03.029.","journal-title":"Epilepsy Behav"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00894-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:07:57Z","timestamp":1772798877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00894-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["894"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00894-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesca Felicia Operto, Grazia Maria Giovanna Pastorino, Bruno Charlier, Viviana Izzo, Iolanda Martino, Romina Moavero, Noemi Mungo, Miriam Olivieri, Ilaria Sammara, and Antonio Gambardella declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All participants and their parents\/caregivers received a clear and detailed explanation about the purposes of the study and procedures involved. Patients and their parents\/caregivers provided their written informed consent. The study protocol was approved by the local ethics committee, in accordance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}